{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:38Z","timestamp":1792789658089,"version":"4.5.0"},"reference-count":72,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 22K16350"],"award-info":[{"award-number":["JP 22K16350"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Despite remarkable advances in the management of RA, there are still unmet needs that rheumatologists need to address. In this review, we focused on difficult-to-treat RA (D2T RA) and late-onset RA (LORA), and summarized their characteristics and management. The prevalence of D2T RA is reported to be 6\u201328% and many factors have been identified as risk factors for D2T RA, including female sex, long disease duration, seropositivity for rheumatoid factor and anti-cyclic citrullinated peptide antibody and their high titer, baseline high disease activity, and comorbidities. D2T RA is broadly divided into inflammatory and non-inflammatory conditions, and clinical features differ according to background. A proportion of D2T RA can be managed with treatment modification, mainly with interleukin-6 receptor inhibitors or Janus kinase inhibitors, but some D2T RA patients have a poor prognosis; thus, the implementation of precision medicine by stratifying patients according to disease status is needed. In the aging society, the epidemiology of RA is changing and the prevalence of LORA is increasing worldwide. LORA has distinct clinical features compared with young-onset RA, such as acute onset, low seropositivity, and high inflammation. The pathogenesis of LORA remains to be elucidated, but proinflammatory cytokines, including interleukin-6, have been reported to be significantly elevated. LORA has several management concerns other than RA itself, such as geriatric syndrome and multimorbidity. The treat-to-target strategy is effective for LORA, but the evidence is still lacking; thus, it is important to accumulate clinical and related basic data to establish the optimal treatment strategy for LORA.<\/jats:p>","DOI":"10.3390\/jcm13247594","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:55:45Z","timestamp":1734069345000},"page":"7594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Unmet Needs and Current Challenges of Rheumatoid Arthritis: Difficult-to-Treat Rheumatoid Arthritis and Late-Onset Rheumatoid Arthritis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-2140","authenticated-orcid":false,"given":"Satoshi","family":"Takanashi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","article-title":"Managing rheumatic and musculoskeletal diseases\u2014Past, present and future","volume":"13","author":"Burmester","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: New opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/annrheumdis-2019-216607","article-title":"CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice","volume":"79","author":"Takanashi","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/art.41597","article-title":"Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016","volume":"73","author":"Chiu","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): A randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"key":"ref_10","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need","volume":"57","author":"Jacobs","year":"2018","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: Results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3899\/jrheum.170773","article-title":"Rheumatologists\u2019 Views and Experiences in Managing Rheumatoid Arthritis in Elderly Patients: A Qualitative Study","volume":"45","author":"Nawrot","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Takanashi, S., Kaneko, Y., Kawahito, Y., Kida, T., Sugihara, T., Kojima, T., Harada, R., Ishitoku, M., Hirata, S., and Hashimoto, M. (2024). A preliminary survey of rheumatologists on the management of late-onset rheumatoid arthritis in Japan. Intern. Med., ahead of print.","DOI":"10.2169\/internalmedicine.3288-23"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","article-title":"Difficult-to-treat rheumatoid arthritis: Contributing factors and burden of disease","volume":"60","author":"Roodenrijs","year":"2021","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/25785826.2021.1928383","article-title":"Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: The KURAMA cohort","volume":"45","author":"Watanabe","year":"2022","journal-title":"Immunol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-021-02560-5","article-title":"Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: Results from a hackathon","volume":"23","author":"Messelink","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","article-title":"Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST Registry","volume":"24","author":"Ochi","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00296-022-05124-1","article-title":"Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis","volume":"42","author":"Yoshii","year":"2022","journal-title":"Rheumatol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","article-title":"Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: A multicentre cohort study","volume":"62","author":"Giollo","year":"2023","journal-title":"Rheumatology"},{"key":"ref_22","first-page":"1114","article-title":"A paradigm of difficult-to-treat rheumatoid arthritis: Subtypes and early identification","volume":"41","author":"Chacur","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e002842","DOI":"10.1136\/rmdopen-2022-002842","article-title":"Difficult-to-treat rheumatoid arthritis (D2T RA): Clinical issues at early stages of disease","volume":"9","author":"Leon","year":"2023","journal-title":"RMD Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s00296-023-05349-8","article-title":"Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: Frequency according to different objective evaluations","volume":"43","author":"Mareco","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-023-03165-w","article-title":"Unveiling difficult-to-treat rheumatoid arthritis: Long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry","volume":"25","author":"Jung","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/art.42767","article-title":"Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes","volume":"76","author":"David","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/03009742.2023.2277542","article-title":"Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study","volume":"53","author":"Michitsuji","year":"2024","journal-title":"Scand. J. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e003808","DOI":"10.1136\/rmdopen-2023-003808","article-title":"Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with \u2018difficult to treat\u2019 rheumatoid arthritis","volume":"10","author":"Bertsias","year":"2024","journal-title":"RMD Open"},{"key":"ref_30","first-page":"1398","article-title":"Challenges and insights in managing difficult-to-treat rheumatoid arthritis: Real-world clinical perspectives","volume":"42","author":"Alp","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1093\/rheumatology\/keae265","article-title":"Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: The ANSWER cohort study","volume":"9","author":"Watanabe","year":"2024","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/annrheumdis-2021-220315","article-title":"Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Takanashi","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","article-title":"Risk profiling for a refractory course of rheumatoid arthritis","volume":"49","author":"Alasti","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis","volume":"17","author":"Buch","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuroscience.2016.06.006","article-title":"Neurobiology of fibromyalgia and chronic widespread pain","volume":"338","author":"Sluka","year":"2016","journal-title":"Neuroscience"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eadk3506","DOI":"10.1126\/scitranslmed.adk3506","article-title":"Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis","volume":"16","author":"Bai","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1111\/1756-185X.14920","article-title":"Effectiveness and safety of rituximab in special types of rheumatoid arthritis","volume":"26","author":"Takanashi","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Takanashi, S., Takeuchi, T., and Kaneko, Y. (2024). Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis. Rheumatology, ahead of print.","DOI":"10.1093\/rheumatology\/keae325"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/rheumatology\/keac645","article-title":"Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis","volume":"62","author":"Duquesne","year":"2023","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/annrheumdis-2022-222370","article-title":"Interferon-\u03b1-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming","volume":"81","author":"Cooles","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/art.38400","article-title":"Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: Biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray","volume":"66","author":"Sanayama","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/ard-2023-225093","article-title":"Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis","volume":"83","author":"Crowson","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/annrheumdis-2022-222339","article-title":"Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease","volume":"81","author":"Wiebe","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/acr.22642","article-title":"Cause-Specific Mortality in Male US Veterans with Rheumatoid Arthritis","volume":"68","author":"England","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/ard-2022-223645","article-title":"Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance","volume":"82","author":"Yamada","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1136\/annrheumdis-2020-217609","article-title":"Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population","volume":"81","author":"Matthijssen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: A nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/mr\/roab013","article-title":"Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?","volume":"32","author":"Uchiyama","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"ref_52","first-page":"330","article-title":"Effects of Aging on Rheumatoid Factor and Anticyclic Citrullinated Peptide Antibody Positivity in Patients with Rheumatoid Arthritis","volume":"50","author":"Takanashi","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.semarthrit.2020.03.018","article-title":"Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: Findings from a prospective observational longitudinal early arthritis cohort study","volume":"50","author":"Humby","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/1756-185X.13428","article-title":"Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort","volume":"22","author":"Murata","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hao, N., Ishikawa, H., Abe, A., Sudo, M., Takamura, S., Otani, H., Ito, S., Nakazono, K., and Murasawa, A. (2024). Unveiling the arthritis divide: Exploring treatment response and impact in late-onset vs. young-onset rheumatoid arthritis. Mod. Rheumatol., ahead of print.","DOI":"10.1093\/mr\/roae069"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/mr\/roae027","article-title":"Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J)","volume":"34","author":"Asai","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000164393","article-title":"Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: A comparison with younger-onset disease","volume":"55","author":"Chen","year":"2009","journal-title":"Gerontology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2004.03.004","article-title":"Inflamm-aging: Autoimmunity, and the immune-risk phenotype","volume":"3","author":"Boren","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0749-0690(02)00023-X","article-title":"The biology of senescence: Potential for prevention of disease","volume":"18","author":"Kirkland","year":"2002","journal-title":"Clin. Geriatr. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41584-022-00768-6","article-title":"Challenges in the management of older patients with inflammatory rheumatic diseases","volume":"18","author":"Boonen","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/mr\/roae011","article-title":"Consensus statement on the management of late-onset rheumatoid arthritis","volume":"34","author":"Kojima","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1093\/rheumatology\/keaa922","article-title":"Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: A 3-year prospective observational study","volume":"60","author":"Sugihara","year":"2021","journal-title":"Rheumatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/rheumatology\/kead083","article-title":"Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: A marginal structural model application","volume":"62","author":"Barbulescu","year":"2023","journal-title":"Rheumatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s10067-020-04929-4","article-title":"Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: From the CHIKARA study","volume":"39","author":"Yamada","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e002111","DOI":"10.1136\/rmdopen-2021-002111","article-title":"Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: A longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank","volume":"8","author":"Hanlon","year":"2022","journal-title":"RMD Open"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in Older Adults","volume":"391","author":"Kim","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","article-title":"Polypharmacy is associated with treatment response and serious adverse events: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","article-title":"Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs","volume":"15","author":"Hanaoka","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fukui, S., Winkelmayer, W.C., Tedeschi, S.K., Marrugo, J., Guan, H., Harrold, L., Litman, H.J., Shinozaki, T., and Solomon, D.H. (2024). Disease activity of rheumatoid arthritis and kidney function decline: A large prospective registry study. Ann. Rheum. Dis., ahead of print.","DOI":"10.1136\/ard-2024-226156"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kojima, M., Kawahito, Y., Sugihara, T., Kojima, T., Harada, R., Hirata, S., Hashimoto, M., Hidaka, T., Ishikawa, H., and Ito, H. (2022). Late-onset rheumatoid arthritis registry study, LORIS study: Study protocol and design. BMC Rheumatol., 6.","DOI":"10.1186\/s41927-022-00322-7"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:20Z","timestamp":1760115260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":72,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247594"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247594","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}